MedTrace Logo

Evaluation of Combined Sensitising and Hypomethylating Therapy Outcomes in AML PDX

NCT06782971 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 25

Last updated 2025-12-08

No results posted yet for this study

Summary

The goal of this observational study is to develop new ways to test new drug combinations to kill tumour cells, in patients with acute myeloid leukemia (AML). The main questions it aims to answer are:

* Are there new ways to speed up discovery of better treatments for AML patients using AML cells from individual from patients in special mice that can accept human tissue?
* Do these mice show treatment responses that are similar to the individual AML patient from whom cells were derived?

Participants with AML who are taking standard of care treatment of venetoclax and azacitidine will be asked to donate blood and bone marrow samples for this study.

Conditions

  • AML - Acute Myeloid Leukemia

Sponsors & Collaborators

  • Cancer Institute NSW

    collaborator UNKNOWN

  • The University of New South Wales

    collaborator OTHER

  • Australian National University

    collaborator OTHER

  • Clinical Hub for Interventional Research (CHOIR)

    lead OTHER_GOV

Principal Investigators

  • John Pimanda, Professor · University of New South Wales

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-06
Primary Completion
2028-02-29
Completion
2030-03-31

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06782971 on ClinicalTrials.gov